JP2024023228A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023228A5 JP2024023228A5 JP2023188623A JP2023188623A JP2024023228A5 JP 2024023228 A5 JP2024023228 A5 JP 2024023228A5 JP 2023188623 A JP2023188623 A JP 2023188623A JP 2023188623 A JP2023188623 A JP 2023188623A JP 2024023228 A5 JP2024023228 A5 JP 2024023228A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- molecule
- hla
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506674P | 2017-05-16 | 2017-05-16 | |
| US62/506,674 | 2017-05-16 | ||
| PCT/US2018/032996 WO2018213467A1 (en) | 2017-05-16 | 2018-05-16 | Manabodies and methods of using |
| JP2019563546A JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563546A Division JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024023228A JP2024023228A (ja) | 2024-02-21 |
| JP2024023228A5 true JP2024023228A5 (enExample) | 2024-08-01 |
| JP7701079B2 JP7701079B2 (ja) | 2025-07-01 |
Family
ID=64274676
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563546A Active JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
| JP2023188623A Active JP7701079B2 (ja) | 2017-05-16 | 2023-11-02 | Ｍａｎａボディおよび使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563546A Active JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11807662B2 (enExample) |
| EP (2) | EP3635000A4 (enExample) |
| JP (2) | JP7381345B2 (enExample) |
| CN (1) | CN111406068A (enExample) |
| AU (2) | AU2018269370B2 (enExample) |
| CA (1) | CA3063905A1 (enExample) |
| WO (1) | WO2018213467A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018213467A1 (en) | 2017-05-16 | 2018-11-22 | The Johns Hopkins University | Manabodies and methods of using |
| EP3683229A1 (en) * | 2019-01-21 | 2020-07-22 | Charité - Universitätsmedizin Berlin | Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy |
| CN114026116A (zh) | 2019-02-20 | 2022-02-08 | 弗雷德哈钦森癌症研究中心 | Ras新抗原特异性结合蛋白及其用途 |
| IL288024B2 (en) | 2019-05-14 | 2025-12-01 | Provention Bio Inc | Methods and compositions for preventing type |
| IL266728B (en) * | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
| WO2021098822A1 (zh) * | 2019-11-21 | 2021-05-27 | 江苏恒瑞医药股份有限公司 | 一种双特异性抗体 |
| EP4077370A4 (en) * | 2019-12-17 | 2024-02-28 | The Johns Hopkins University | MANABODIES TARGETING TUMOR ANTIGENS AND METHODS OF USE |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| JP2023529853A (ja) * | 2020-06-17 | 2023-07-12 | ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー | キメラ抗原受容体（ｃａｒ）ｔ細胞療法を増強するための組成物および方法 |
| WO2022119955A1 (en) * | 2020-12-01 | 2022-06-09 | The Johns Hopkins University | Methods and materials for treating t cell cancers |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| CN116574748B (zh) * | 2023-07-10 | 2023-09-12 | 昆明医科大学 | 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法 |
| WO2025106598A1 (en) * | 2023-11-13 | 2025-05-22 | Clasp Therapeutics, Inc. | Modified mana-tces targeting tumor antigens and engaging t cell receptors, and methods of using thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| US6630584B1 (en) | 2000-03-16 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Single chain antibody against mutant p53 |
| US20030223994A1 (en) | 2002-02-20 | 2003-12-04 | Hoogenboom Henricus Renerus Jacobus Mattheus | MHC-peptide complex binding ligands |
| JP3738308B2 (ja) | 2002-11-29 | 2006-01-25 | 篤 村口 | 抗原特異的リンパ球抗原受容体遺伝子のクローニング方法 |
| CA2530172A1 (en) | 2003-06-27 | 2005-02-10 | Abgenix, Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| US20050042218A1 (en) | 2003-07-10 | 2005-02-24 | Vaccinex, Inc. | MHC class I - peptide-antibody conjugates with modified beta2-microglobulin |
| JP4579836B2 (ja) * | 2004-01-23 | 2010-11-10 | 株式会社グリーンペプタイド | 上皮細胞増殖因子受容体（ｅｇｆｒ）由来ペプチド |
| US20060034850A1 (en) | 2004-05-27 | 2006-02-16 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| CA2569509C (en) | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| ATE437185T1 (de) | 2005-03-25 | 2009-08-15 | Univ Ramot | Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon |
| CN101228187A (zh) | 2005-03-25 | 2008-07-23 | 特拉维夫大学拉莫特有限公司 | 针对突变p53的共同表位的人合成单链抗体及其用途 |
| EA014025B1 (ru) | 2005-09-12 | 2010-08-30 | Новиммун С.А. | Композиции антитела против cd3 |
| RU2008129827A (ru) | 2005-12-21 | 2010-01-27 | МЕДИММЬЮН, ЭлЭлСи (US) | МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ |
| KR101944557B1 (ko) | 2011-02-11 | 2019-01-30 | 메모리얼 슬로안 케터링 캔서 센터 | 에이치엘에이 제한된, 펩타이드특이성 항원 결합 단백질 |
| CN107827985A (zh) | 2011-05-21 | 2018-03-23 | 宏观基因有限公司 | 能够与人和非人cd3结合的cd3结合分子 |
| EP2794658B1 (en) * | 2011-12-19 | 2017-03-15 | Synimmune GmbH | Bispecific antibody molecule |
| EP2961831B1 (en) | 2013-02-26 | 2020-06-10 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| AU2015239069B2 (en) | 2014-04-03 | 2020-02-20 | Cellectis | CD33 specific Chimeric Antigen Receptors for cancer immunotherapy |
| US9611325B2 (en) | 2014-07-21 | 2017-04-04 | Wuhan Yzy Biopharma Co., Ltd. | Construction and application of bispecific antibody HER2xCD3 |
| PT3223850T (pt) | 2014-11-26 | 2020-04-13 | Us Health | Receptores de células t anti-kras mutado |
| WO2016154047A2 (en) * | 2015-03-20 | 2016-09-29 | Memorial Sloan-Kettering Cancer Center | Monoclonal antigen-binding proteins to intracellular oncogene products |
| CA2980292A1 (en) * | 2015-03-23 | 2016-09-29 | The Johns Hopkins University | Hla-restricted epitopes encoded by somatically mutated genes |
| WO2016166139A1 (en) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
| MX2017014700A (es) * | 2015-05-20 | 2018-08-15 | Broad Inst Inc | Neoantigenos compartidos. |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| SG10202110887PA (en) * | 2015-06-09 | 2021-11-29 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla |
| GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| CN108350059B (zh) * | 2015-09-15 | 2021-10-08 | 美国卫生和人力服务部 | 识别hla-cw8限制性突变kras的t细胞受体 |
| TN2018000266A1 (en) | 2016-02-03 | 2020-01-16 | Amgen Res Munich Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs. |
| IL313507A (en) | 2016-02-03 | 2024-08-01 | Amgen Res Munich Gmbh | Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof |
| SG10201913583QA (en) | 2016-08-23 | 2020-02-27 | Univ California | Proteolytically cleavable chimeric polypeptides and methods of use thereof |
| US20190240257A1 (en) | 2016-10-13 | 2019-08-08 | The Johns Hopkins University | Compositions and methods for identifying functional anti-tumor t cell responses |
| US20200325244A1 (en) * | 2020-05-18 | 2020-10-15 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| WO2018213467A1 (en) | 2017-05-16 | 2018-11-22 | The Johns Hopkins University | Manabodies and methods of using |
| KR102809909B1 (ko) | 2017-09-29 | 2025-05-22 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법 |
| MA51043A (fr) | 2017-12-04 | 2020-10-14 | Us Health | Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée |
| EP4077370A4 (en) | 2019-12-17 | 2024-02-28 | The Johns Hopkins University | MANABODIES TARGETING TUMOR ANTIGENS AND METHODS OF USE |
| CN111344015B (zh) | 2019-12-23 | 2022-09-30 | 深圳市人民医院 | 一种用于癌症治疗的光纳米疫苗及其制备方法和应用 |
-
2018
- 2018-05-16 WO PCT/US2018/032996 patent/WO2018213467A1/en not_active Ceased
- 2018-05-16 CA CA3063905A patent/CA3063905A1/en active Pending
- 2018-05-16 CN CN201880047554.3A patent/CN111406068A/zh active Pending
- 2018-05-16 EP EP18802867.4A patent/EP3635000A4/en not_active Withdrawn
- 2018-05-16 EP EP25190769.7A patent/EP4644427A2/en active Pending
- 2018-05-16 US US16/614,005 patent/US11807662B2/en active Active
- 2018-05-16 JP JP2019563546A patent/JP7381345B2/ja active Active
- 2018-05-16 AU AU2018269370A patent/AU2018269370B2/en active Active
-
2023
- 2023-09-25 US US18/473,695 patent/US20240294648A1/en active Pending
- 2023-11-02 JP JP2023188623A patent/JP7701079B2/ja active Active
-
2025
- 2025-05-21 AU AU2025203767A patent/AU2025203767A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024023228A5 (enExample) | ||
| JP2025065142A5 (enExample) | ||
| JP2025023921A (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP2023123502A5 (enExample) | ||
| JP2019525771A5 (enExample) | ||
| WO2021008610A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| RU2019126655A (ru) | Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль | |
| JP2018538277A5 (enExample) | ||
| JP2018526033A5 (enExample) | ||
| JP2015527070A5 (enExample) | ||
| JP2020512973A5 (enExample) | ||
| JP2019535262A5 (enExample) | ||
| JPWO2019157533A5 (enExample) | ||
| CN105194661A (zh) | 时空可调性抑制病理性靶细胞的系统 | |
| CN115066274A (zh) | 三价结合分子 | |
| JPWO2022133169A5 (enExample) | ||
| IL274806B1 (en) | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof | |
| JPWO2021184673A5 (enExample) | ||
| JPWO2020051493A5 (enExample) | ||
| JPWO2019191120A5 (enExample) | ||
| JPWO2021127184A5 (enExample) | ||
| JPWO2020104676A5 (enExample) | ||
| JPWO2020037066A5 (enExample) | ||
| WO2024037628A1 (zh) | 一种双特异性抗体及其应用 | |
| JPWO2023044456A5 (enExample) |